News

Expanding global market access, reimbursement, and communications solutions.

Draft terms of reference and membership of panel now on bmj.com

This month, let's look at a quality metric that's useful for tracking both protocol and site performance: subject retention percentage.

Amidst all the talk about reducing the time and scope of clinical trials to accelerate drug testing and approval, medical product development still requires researchers and regulators to "get the right answer".

ICON announced that Aptiv Solutions, an ICON company for the design and implementation of adaptive trials, has released ADDPLAN DF 3.0

ICON plc, announced Aptiv Solutions, an ICON plc company leading the design and implementation of adaptive trials, has released ADDPLAN DF 3.0

PRA announced the addition of capabilities and services to its Lenexa, KS location.

Immunochemistry Services Now Available in Kansas

Thomas Verish, Group Director of Data Operations Services at Bristol-Myers Squibb, elaborated on their risk-based monitoring pilot.

Medidata

With the rationale of making Europe a better environment for clinical research, the European Union is taking steps towards greater transparency of clinical trial data.

The so-called n-of-1 trial provides data on individual responses to treatment options...

It is estimated that mobile penetration now stands at 96% globally.

Sponsor companies and service providers have embraced more strategic management of their clinical supplies while regulatory pressures and the volume of global clinical trial activity have increased.

The MRC Clinical Trials Unit at University College London has won the top research prize at the 2014 BMJ Awards

In my previous blog "From Science to Fiction" (ACTO, April 15, 2014), I discussed the trials and tribulations of unlearning the scientific writing style...

What is quality? For Patricia Leuchten, CEO of The Avoca Group, and the members of its Quality Consortium, quality can be a platform for innovation and change.

CTMS applications have many features, but for your organization, different features will hold different levels importance.

MedAvanta offers software that guides investigative sites in rater reliability skills.

ACRP is officially partnering with the European Clinical Research Infrastructures Network in honoring the extraordinary contributions of clinical researchers worldwide

The Gift of Participation, a guide for patients and family about the clinical trials has been updated to include new information.

As I was trying out a series of corrective lenses at an optometrist last week to choose the one that finally provided me the clarity that I was looking for, it made me pose a profound question to myself about perception and reality.

MedAvante, Inc., the world's leading provider of centralized assessments and quality control in clinical trials of treatments for central nervous system (CNS) disorders, announced the Virgil Investigative Study Platform for use by drug developers and their global cohort of trial sites.

The Association of Clinical Research Professionals (ACRP) is officially partnering with the European Clinical Research Infrastructures Network (ECRIN) in honoring the extraordinary contributions of clinical researchers worldwide on International Clinical Trials? Day--May 20. ECRIN launched the day in 2006 for organizations, clinical research professionals, and the public to acknowledge the life changing achievements that result from the work performed by clinical researchers.

While at the 2014 Bio IT World conference, I had the opportunity to interview Pek Lum, Ayasdi's Chief Data Scientist.

The Association of Clinical Research Professionals (ACRP) is officially partnering with the European Clinical Research Infrastructures Network (ECRIN) in honoring the extraordinary contributions of clinical researchers worldwide on International Clinical Trials? Day.

According to the study, mean clinical phase time was 8.9 months longer for new drugs in multi-firm, risk-sharing clinical development relationships, and total (clinical plus regulatory review) phase time was 9.5 months longer, compared to new drugs that did not involve these relationships.